miR‑185‑5p inhibits F‑actin polymerization and reverses epithelial mesenchymal transition of human breast cancer cells by modulating RAGE

Molecular Medicine Reports
Chonggao YinYunbo Sun

Abstract

In our previous study, advanced glycosylation end‑product specific receptor (RAGE) was observed to bind to S100A8/A9 and cause epithelial mesenchymal transition (EMT). The results from target gene prediction revealed that microRNA (miR)‑185‑5p had a RAGE binding site. However, the function of miR‑185‑5p in the invasion and migration of breast cancer remains ambiguous. In the present study, the expression of miR‑185‑5p was examined in breast cancer tissues and cells. Clinical features revealed a negative correlation between miR‑185‑5p and tumor size, as well as in tumor differentiation and lymph node metastasis in breast cancer. In addition, miR‑185‑5p was negatively associated with RAGE, and this miRNA reversed the EMT of breast cancer by modulating RAGE in vitro. In addition, miR‑185‑5p inhibited the S100A8/A9‑induced EMT of breast cancer cells by the nuclear factor‑κB/Snail signaling pathway. Notably, miR‑185‑5p upregulation inhibited the F‑actin polymerization induced by S100A8/A9 in breast cancer. Furthermore, overexpression of miR‑185‑5p and reduction of RAGE inhibited lung metastasis node in vivo. Thus, miR‑185‑5p represents a potential therapeutic target in breast cancer by modulating RAGE.

References

Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Jun 22, 2005·Neoplasia : an International Journal for Oncology Research·Ichiro OkamotoHubert Pehamberger
Jul 19, 2006·Biochemical Pharmacology·Christoffer GebhardtJochen Hess
Jan 27, 2009·Cancer Metastasis Reviews·Mahmut Yilmaz, Gerhard Christofori
Jun 24, 2010·Cancer Research·Anastasia Z KaleaBarry I Hudson
Jan 14, 2011·Molecular Cancer Research : MCR·Mie IchikawaGeetha Srikrishna
Dec 31, 2011·Biochemical and Biophysical Research Communications·Indira ElangovanMunirathinam Gnanasekar
Jul 28, 2012·Current Cancer Drug Targets·Hailin TangMinghua Wu
Sep 26, 2012·Oncotarget·Raghuveer Singh Mali, Reuben Kapur
May 8, 2013·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Qiaoming ZhiYuting Kuang
Jul 13, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jung Hwan YoonWon Sang Park
Oct 12, 2013·CA: a Cancer Journal for Clinicians·Carol DeSantisAhmedin Jemal
Oct 31, 2013·Current Cancer Drug Targets·Moorthy P PonnusamySurinder K Batra
Feb 22, 2014·Nature Reviews. Molecular Cell Biology·Samy LamouilleRik Derynck
Mar 29, 2014·British Journal of Pharmacology·C M FifeM Kavallaris
May 14, 2014·Journal of Molecular and Cellular Cardiology·Appledene OsbourneGene H Kim
Jun 10, 2014·The American Journal of Pathology·Ximena V QadirTong Wu
Sep 23, 2014·The International Journal of Biochemistry & Cell Biology·Emmanuel J SilvaMark C Herzberg
Sep 25, 2014·Science Signaling·David M Gonzalez, Damian Medici
Oct 19, 2014·Cancer Research·Xuebo ChenBehnam Badie
Sep 1, 2015·American Journal of Physiology. Gastrointestinal and Liver Physiology·Rongrong JingMing Cui

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection
xenografts

Software Mentioned

TargetScan
SPSS
ImageJ

Related Concepts

Related Feeds

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.